OTC Markets OTCPK - Delayed Quote USD
Inventiva S.A. (IVEVF)
As of October 16 at 4:00 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Frederic Cren | Co-Founder, CEO & Chairman | 535.08k | -- | 1966 |
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy CEO & Director | 462.12k | -- | 1962 |
| Mr. Jean Volatier | Deputy GM & CFO | -- | -- | 1964 |
| Ms. Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer | -- | -- | 1971 |
| Mr. Eric Duranson L.L.M. | General Counsel | -- | -- | 1974 |
| Ms. Nathalie Harroy | Head of Human Resources | -- | -- | 1967 |
| Dr. Kristina Meyer Ph.D. | Executive VP and Business Development & Alliance Management | -- | -- | -- |
| Dr. Michael Cooreman | Chief Medical Officer | -- | -- | 1958 |
| Ms. Pascaline Clerc Ph.D. | Executive Vice President of Strategy & Corporate Affairs | -- | -- | 1980 |
Inventiva S.A.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 123
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Corporate Governance
Inventiva S.A.’s ISS Governance QualityScore as of October 1, 2024 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 9; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
September 25, 2024 at 8:00 PM UTC
Inventiva S.A. Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
ESLAW Estrella Immunopharma, Inc.
0.1225
+23.74%
KLTOW Klotho Neurosciences, Inc.
0.0300
-35.40%
CYCCP Cyclacel Pharmaceuticals, Inc.
7.30
0.00%
NKGNW NKGen Biotech, Inc.
0.0413
+42.41%
ESLA Estrella Immunopharma, Inc.
0.8700
0.00%
IPSC Century Therapeutics, Inc.
1.5788
-1.32%
ANAB AnaptysBio, Inc.
34.90
-0.23%
GLPG Galapagos NV
30.54
-0.71%
MRSN Mersana Therapeutics, Inc.
2.1050
+0.24%
XENE Xenon Pharmaceuticals Inc.
44.02
-1.87%